Andrew Stevens

Technik-/Wissenschafts-/F&E-Leiter bei ViRexx Medical Corp.

Health Technology

Profil

Andrew Stevens is Vice President of Clinical/Regulatory for ViRexx Medical Corp.
Prior to joining ViRexx, he was Vice President of Product Development at Cytovax, Inc. Previously, he was Vice President of Clinical Research and Regulatory Affairs with ViRexx and Director of Clinical and Regulatory Affairs and Director of Clinical and Professional Affairs at Biomira, Inc. Dr. Stevens holds a BS in Pharmacy and a PhD in Bionucleonics.

Aktive Positionen von Andrew Stevens

Unternehmen	Position	Beginn
ViRexx Medical Corp. ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada.	Technik-/Wissenschafts-/F&E-Leiter	-

Alle aktiven Positionen von Andrew Stevens

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Andrew Stevens im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
ViRexx Medical Corp. ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada.	Health Technology